Thiophenib Tosylate

对甲苯磺酸噻尔非尼

Report date: 2025/06/05 16:57:50
NME

Base Information

Drug NameThiophenib Tosylate
Drug Alias Name噻尔非尼Thiophenib TosilateSIM-81OSI-930SIM-930
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor beta inhibitorsVascular endothelial growth factor receptor 2 inhibitors
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor betaVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesAstellas Pharma Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma IncJiangsu Simcere Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksDrugBank